← All funds
North America
IFSL Marlborough US Focus Fund
Managed by Marlborough Investment Management Limited
Latest factsheet
Aug 2026
Fund size
£19.1m
Yearly charge
0.85%
Manager fee
–
Income yield
1.38%
Holdings
55
Launched
31 Dec 2012
The aim of the Fund is to provide capital growth, that is, to increase the value of your investment, and income, which is money paid out from your investment, such as dividends from shares and interest from bonds, over a minimum of 5 years, however there is no certainty this will be achieved.
Brad Weafer · Tim Farina · Tim Robinson
Cumulative performance
| Period | Fund | Sector average | Benchmark | vs sector |
|---|---|---|---|---|
| 1Y | -1.50% | +13.80% | – | Bottom 25% |
| 3Y | +22.90% | +49.40% | – | Bottom 25% |
| 5Y | +36.70% | +62.40% | – | Bottom 25% |
| 10Y | +174.40% | +228.70% | – | Bottom 25% |
Calendar-year performance
| 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| +8.50% | +2.50% | +19.30% | +4.50% | -1.50% |
Top holdings
| # | Holding | Weight | |
|---|---|---|---|
| 1 | ALPHABET | 3.40% | |
| 2 | AMAZON.COM | 2.90% | |
| 3 | APPLE | 2.60% | |
| 4 | AMPHENOL CORPORATION | 2.60% | |
| 5 | ARISTA NETWORKS INC | 2.50% | |
| 6 | BROADCOM | 2.50% | |
| 7 | COMFORT SYSTEMS USA | 2.10% | |
| 8 | JONES LANG LASALLE INCORPORATED | 2.10% | |
| 9 | NEUROCRINE BIOSCIENCES INC | 2.10% | |
| 10 | CDW CORPORATION | 2.10% |
Portfolio breakdown
Geography
| United States | 97.50% | |
| Ireland | 1.80% | |
| Cash | 0.70% |
Asset allocation
| International Equities | 99.30% | |
| Cash and Equivalents | 0.70% |
Market cap
| Mega (>20bn) | 44.00% | |
| Large (5bn-20bn) | 28.60% | |
| Medium (1bn-5bn) | 14.30% | |
| Small (250m-1bn) | 2.10% | |
| Micro (<250m) | 0.00% |
Share classes
| Class | ISIN | SEDOL | Type | Hedged | Manager fee | Yearly charge | Minimum |
|---|---|---|---|---|---|---|---|
| P Inc | GB00B906QV32 | B906QV3 | inc | – | – | 0.82% | – |
Source factsheets
| Month | Published by the manager | Read on |
|---|---|---|
| Aug 2026 | View original factsheet ↗ | 13 Sept 2026 |
| Jul 2026 | View original factsheet ↗ | 21 Aug 2026 |